Основная статистика
| CIK | 1339005 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Femasys Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 27, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT FEMASYS INC. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT FEMASYS INC. Warrant Shares: [●] Issue Date: August 27, 2025 Initial Exercise Date: August 27, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| August 27, 2025 |
Exhibit 1.1 FEMASYS INC. 10,434,586 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 11,750,000 SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE WARRANTS TO PURCHASE 22,184,586 SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE Underwriting Agreement August 25, 2025 JonesTrading Institutional Services LLC Laidlaw & Company (UK) Ltd. As the Representatives of the |
|
| August 27, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-289722 PROSPECTUS FEMASYS INC. 10,434,586 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 11,750,000 SHARES OF COMMON STOCK COMMON WARRANTS TO PURCHASE 22,184,586 SHARES OF COMMON STOCK 33,934,586 SHARES OF COMMON STOCK UNDERLYING THE PRE-FUNDED WARRANTS AND COMMON WARRANTS We are offering 10,424,586 shares of our com |
|
| August 27, 2025 |
REPRESENTATIVE’S PURCHASE WARRANT FEMASYS INC. Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR TH |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 Femasys Inc. |
|
| August 27, 2025 |
COMMON STOCK PURCHASE WARRANT FEMASYS INC. Exhibit 4.3 COMMON STOCK PURCHASE WARRANT FEMASYS INC. Warrant Shares: [●] Issue Date: August 27, 2025 Initial Exercise Date: August 27, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| August 21, 2025 |
REPRESENTATIVE’S PURCHASE WARRANT FEMASYS INC. Exhibit 4.10 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| August 21, 2025 |
COMMON STOCK PURCHASE WARRANT FEMASYS INC. Exhibit 4.12 COMMON STOCK PURCHASE WARRANT FEMASYS INC. Warrant Shares: [●] Issue Date: August [●], 2025 Initial Exercise Date: August [●], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| August 21, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT FEMASYS INC. Exhibit 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT FEMASYS INC. Warrant Shares: [●] Issue Date: August [●], 2025 Initial Exercise Date: August [●], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| August 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par valu |
|
| August 21, 2025 |
As filed with the Securities and Exchange Commission on August 21, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 21, 2025 Registration No. |
|
| August 21, 2025 |
Exhibit 1.1 FEMASYS INC. [ ] SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE [ ] SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE WARRANTS TO PURCHASE [ ] SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE Underwriting Agreement August [ ], 2025 JonesTrading Institutional Services LLC Laidlaw & Company (UK) Ltd. As the Representatives of the several Underwriter |
|
| August 20, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Femasys Secures UK Regulatory Approval of FemBloc® Permanent Birth Control -Advances European commercialization strategy following CE mark approval- ATLANTA – August 20, 2025 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par val |
|
| August 20, 2025 |
TABLE OF CONTENTS Registration No. 333- As filed with the Securities and Exchange Commission on August 19, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 3841 11-3713499 (State or other jurisdiction of |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 8, 2025 |
TABLE OF CONTENTS CONFIDENTIAL TREATMENT REQUESTED BY FEMASYS INC.PURSUANT TO 17 C.F.R SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on August 8, 2025 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURI |
|
| August 8, 2025 |
Exhibit 99.1 Femasys Announces Second Quarter Financial Results for 2025 - Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio - ATLANTA, August 8, 2025 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial resul |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492. Femasys I |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 6, 2025 |
Exhibit 99.1 Femasys Secures First European Order for FemBloc®, Marking Strategic Milestone in Global Expansion -Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates- ATLANTA – August 6, 2025 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and |
|
| July 18, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2025 Femasys Inc. |
|
| July 3, 2025 |
Execution Version ANY MARKET PURCHASE AGREEMENT Exhibit 10.1 Execution Version ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “Agreement”), dated as of June 30, 2025 (the “Execution Date”), by and between Femasys Inc., a Delaware corporation (the “Company”), and Alumni Capital LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, the Compan |
|
| July 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry For |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 Femasys Inc. |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| July 3, 2025 |
FEMASYS INC., AS ISSUER, AS TRUSTEE, DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS Exhibit 4.3 FEMASYS INC., AS ISSUER, AND [TRUSTEE], AS TRUSTEE, INDENTURE DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 Section 2.3 |
|
| July 1, 2025 |
Exhibit 99.1 Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic - Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions - ATLANTA – July 1, 2025 – Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2025 |
Exhibit 99.1 Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control -European CE mark approval of the entire FemBloc®system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women- ATLANTA – June 25, 2025 – Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressi |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 17, 2025 |
Exhibit 99.1 Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth -New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio- ATLANTA – June 17, 2025 – Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 2, 2025 |
FEMASYS INC. 3,600,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE Underwriting Agreement Exhibit 1.1 Execution Version FEMASYS INC. 3,600,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE Underwriting Agreement May 29, 2025 JonesTrading Institutional Services LLC As the Representative of the several Underwriters listed in Schedule A hereto c/o JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, New York 10013 Ladies and Gentlemen: Femasys Inc., a Delawa |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2025 Femasys Inc. |
|
| June 2, 2025 |
COMMON STOCK PURCHASE AGREEMENT BY AND AMONG FEMASYS INC. THE PURCHASERS May 29, 2025 Exhibit 10.1 Execution Version COMMON STOCK PURCHASE AGREEMENT BY AND AMONG FEMASYS INC. AND THE PURCHASERS May 29, 2025 TABLE OF CONTENTS Page 1.1. Purchase and Sale 1 1.2. Closing 1 3.1. Organization 17 3.2. Authorization 17 3.3. No Conflict 17 3.4. Consents 17 3.5. Residency 17 3.6. Brokers and Finders 18 3.7. Investment Representations and Warranties 18 3.8. Intent 18 3.9. Investment Experienc |
|
| June 2, 2025 |
FEMASYS INC. 3,600,000 SHARES OF COMMON STOCK TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-266001 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2022) FEMASYS INC. 3,600,000 SHARES OF COMMON STOCK We are offering 3,600,000 shares of our common stock, par value $0.001 per share (“common stock”). The purchase price for each share is $0.85. Our common stock is listed on the Nasdaq Capital Market under the symbol “ |
|
| June 2, 2025 |
REPRESENTATIVE’S PURCHASE WARRANT FEMASYS INC. Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR TH |
|
| May 29, 2025 |
SUBJECT TO COMPLETION, DATED MAY 29, 2025 TABLE OF CONTENTS The information in this prospectus supplement is not complete and may be changed. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492. Femasys |
|
| May 8, 2025 |
Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update - Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) - ATLANTA, May 8, 2025 - Femasys Inc. (NASDAQ: FEMY), |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| March 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
FEMASYS INC. INSIDER TRADING POLICY Exhibit 19.1 FEMASYS INC. INSIDER TRADING POLICY In order to take an active role in the prevention of insider trading violations by officers, directors, employees and other related individuals of Femasys Inc. (the “Company”), the Company has adopted this Insider Trading Policy (this “Policy”). Statement of Intent The Company opposes the misuse of material nonpublic information in the trading of se |
|
| March 27, 2025 |
Exhibit 99.1 Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain - ATLANTA, March 27, 2025 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. ( |
|
| March 18, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 18, 2025 |
Exhibit 99.1 Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® - ATLANTA – March 18, 2025 – Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldw |
|
| March 13, 2025 |
Exhibit 99.1 Femasys Announces FemBloc® Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach -First-in-world approval of FemBloc® delivery system for women seeking permanent birth control- ATLANTA – March 13, 2025 – Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet |
|
| March 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femas |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 12, 2024 |
Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - Company accelerated commercialization with significant new partnerships both in the U.S. and Europe - ATLANTA, November 12, 2024 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of i |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 12, 2024 |
Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - Company accelerated commercialization with significant new partnerships both in the U.S. and Europe - ATLANTA, November 12, 2024 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of i |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 29, 2024 |
Exhibit 99.1 Investor presentation October 2024 NASDAQ: FEMY Disrupting Convention in Women’s Reproductive Health Through Continuous Innovation This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 11, 2024 |
Exhibit 99.1 Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products ATLANTA – September 11, 2024 - Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant |
|
| September 9, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 9, 2024 |
Exhibit 99.1 Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial ATLANTA – September 9, 2024 - Femasys |
|
| August 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 30, 2024 |
Exhibit 99.1 Investor presentation August 2024 NASDAQ: FEMY Disrupting Convention in Women’s Reproductive Health Through Continuous Innovation This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and |
|
| August 29, 2024 |
Exhibit 99.1 Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution ATLANTA, August 29, 2024 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 8, 2024 |
Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update - Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio - ATLANTA, August 8, 2024 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women wo |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys In |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 20, 2024 |
Exhibit 99.1 Femasys Receives CE Mark Approval for Four of its Women’s Health Products, Clearing the Path for the Company to Begin Commercialization Efforts in Europe ATLANTA – June 20, 2024 - Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and di |
|
| June 7, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 9, 2024 |
Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update - Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues - ATLANTA, May 9, 2024 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of wome |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys I |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 24, 2024 |
Exhibit 99.1 Investor presentation April 2024 NASDAQ: FEMY Disrupting Convention in Women’s Reproductive Health Through Continuous Innovation This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and a |
|
| April 24, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| April 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 28, 2024 |
Exhibit 99.1 Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update - Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 - ATLANTA, March 28, 2024 - Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women wo |
|
| March 28, 2024 |
Exhibit 97.1 FEMASYS INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Femasys Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this p |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. ( |
|
| March 20, 2024 |
Exhibit 99.1 Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility - In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed - - FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate - - Of those with a successful pregnancy, a majority required only |
|
| March 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 6, 2024 |
Exhibit 99.1 Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution - Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF - - Ongoing uncertainty following recent Alabama Supreme Court Ruling creates continued anticipation with top-line pivotal data expected to |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 FEMASYS INC (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 28, 2024 |
Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectation |
|
| February 28, 2024 |
Exhibit 99.2 Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF - Femasys readies for the commercial launch of FemaSeed® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) - - Femasys to announce top-line data from recently completed pivo |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 6, 2024 |
Exhibit 99.1 Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer - Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed - ATLANTA, February 6, 2024 - Femasys Inc. (NASDAQ: FEMY), a |
|
| February 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 8, 2023 |
Femasys Inc. 18,111,861 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-275823 PROSPECTUS Femasys Inc. 18,111,861 Shares Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 18,111,861 shares of our common stock, par value $0.001 per share. These shares consist of (i) 6,501,695 shares of com |
|
| December 6, 2023 |
Securities and Exchange Commission December 6, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par val |
|
| November 29, 2023 |
Exhibit 99.1 Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, November 28, 2023 - Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, ac |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 22, 2023 |
FEMY / Femasys Inc / PharmaCyte Biotech, Inc. - FORM SC-13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 FEMASYS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 31447E 105 (CUSIP Number) Kathy Lee-Sepsick c/o Femasys Inc. 3950 Johns Creek Court, Suite 100 Suwanee, GA (770) 500-3910 (Name, Address and Telephone Number of Person Authorized to Re |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 15, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as November 14, 2023, is by and among Femasys Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer is executing and delivering this |
|
| November 15, 2023 |
Form of Registration Rights Agreement Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 14, 2023, is by and among Femasys Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of November 14, |
|
| November 15, 2023 |
Form of Collaboration Agreement Exhibit 10.4 COLLABORATION AGREEMENT This Collaboration Agreement (“Agreement”) is effective as of the date of last signature below (“Effective Date”) and is by and between PharmaCyte Biotech, Inc., a Nevada corporation with its principal place of business at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169, United States (“PharmaCyte”), and Femasys Inc., a Delaware corporation, having i |
|
| November 15, 2023 |
Exhibit 4.2 [FORM OF SERIES B WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE R |
|
| November 15, 2023 |
false000133900500013390052023-11-082023-11-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 15, 2023 |
Exhibit 99.1 Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lea |
|
| November 15, 2023 |
Exhibit 10.2 FORM OF SENIOR UNSECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A |
|
| November 15, 2023 |
Exhibit 4.1 [FORM OF SERIES A WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE R |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 14, 2023 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update - 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization - - Patient enrollment has commenced in landmark, pivotal FINALE trial for lead product candidate, FemBloc®, with academic sites enrolling t |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femas |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 11, 2023 |
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Femasys Inc. Regains Compliance with Nasdaq Listing Requirements ATLANTA, October 11, 2023 - Femasys Inc. (Nasdaq: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has it |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 3, 2023 |
Piper Sandler The date of this prospectus supplement is October 3, 2023. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-266001 PROSPECTUS SUPPLEMENT (to the prospectus dated July 12, 2022) Up to $16,700,000 Common Stock We have entered into an Equity Distribution Agreement, dated July 1, 2022 (the “Equity Distribution Agreement”), with Piper Sandler & Co. (“Piper Sandler” or the “Sales Agent”) relating to shares of our common stock offered by |
|
| September 27, 2023 |
Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation September 2023 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectatio |
|
| September 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 27, 2023 |
Exhibit 99.2 Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution - The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed® is an innovative infertility treatm |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2023 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update - Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® - Three product approvals achieved in Canada for FemaSeed®, FemCerv® and FemCath® products during the second quarter - Raised $3.9 million in a registered direct offering ATLA |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys In |
|
| August 7, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ D |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 3, 2023 |
Exhibit 99.1 Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc - First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial - ATLANTA, August 3, 2023 – Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidate |
|
| July 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| July 27, 2023 |
Exhibit 99.1 Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control - FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control - ATLANTA, July 27, 2023 – Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| July 14, 2023 |
Femasys Inc. 3,388,525 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-272876 PROSPECTUS Femasys Inc. 3,388,525 Shares Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 3,388,525 shares of our common stock, par value $0.001 per share. These shares consist of (i) 3,196,722 shares of commo |
|
| July 12, 2023 |
July 12, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 7, 2023 |
As filed with the Securities and Exchange Commission on July 7, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 7, 2023 Registration No. |
|
| July 7, 2023 |
July 7, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par val |
|
| June 26, 2023 |
Exhibit 99.2 Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women - Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 – Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minim |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 26, 2023 |
Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation June 2023 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations an |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par value |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 15, 2023 |
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences Exhibit 99.1 Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences - Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of biotechnology company, Bicycle Therapeutics both join Femasys’ Board of Directors – ATLANTA, June 15, 2023 – Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet |
|
| June 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 8, 2023 |
Exhibit 99.1 Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada - FemCath® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast - - FemCath is used in conjunction with Femasys’ FemVue® product as a baseline diagnostic test for infertility prior to therapeutic options like FemaSeed®, our insemination |
|
| June 2, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 Femasys Inc. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv |
|
| May 15, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys I |
|
| May 11, 2023 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023 -Received regulatory approval for both FemaSeed® and FemCerv® products from Health Canada- ATLANTA, May 11, 2023 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies |
|
| May 11, 2023 |
Exhibit 99.2 Disrupting Convention in Women’s Health Through Continuous Innovation May 2023 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 4, 2023 |
Exhibit 99.1 Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada - FemCerv® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity - ATLANTA, May 3, 2023 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of product |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 20, 2023 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Femasys Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 20, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-266001 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2022) 1,318,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,878,722 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,318,000 shares (the “Shares”) of our common stock, $0.001 par value per share (th |
|
| April 20, 2023 |
COMMON STOCK PURCHASE WARRANT Femasys Inc. Exhibit 4.2 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| April 20, 2023 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Femasys Inc. EX-4.1 2 ny20008824x2ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 EXHIBIT A-1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Femasys Inc. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditio |
|
| April 20, 2023 |
EX-10.1 6 ny20008824x2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 18, 2023, between Femasys Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, |
|
| April 20, 2023 |
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules ATLANTA, April 19, 2023 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has entered into a def |
|
| April 18, 2023 |
Exhibit 99.1 Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada - FemaSeed® is the first-ever, first-line approach designed to deliver sperm directly where contraception occurs ATLANTA, April 18, 2023 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that in |
|
| April 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 5, 2023 As filed with the Securities and Exchange Commission on April 5, 2023 Registration No. |
|
| April 5, 2023 |
EX-FILING FEES 4 brhc10050798ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registra |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 31, 2023 |
Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation March 2023 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations a |
|
| March 30, 2023 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update - 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys’ FemBloc® for permanent birth control and FemaSeed® for infertility - The commercial launches of FemCathTM a |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. ( |
|
| March 30, 2023 |
FIRST AMENDEMENT TO THE AMENDED AND RESTATED BYLAWS OF FEMASYS INC. Exhibit 3.1 FIRST AMENDEMENT TO THE AMENDED AND RESTATED BYLAWS OF FEMASYS INC. THIS FIRST AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF FEMASYS INC., a Delaware corporation (the “Corporation”), is made as of this 29th day of March, 2023. 1. The first sentence of Section 5 of Article I of the Amended and Restated Bylaws of the Corporation is hereby amended and restated in its entirety as follows |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 21, 2022 |
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device Exhibit 99.1 Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device -FemCath? is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast - - FemCath is used in conjunction with FemVue as a baseline diagnostic test for infertility - ATLANTA, December 19, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aim |
|
| December 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femas |
|
| November 10, 2022 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update -FemaSeed? de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility- -Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization (PMA) for FemBl |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 20, 2022 |
Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation October 2022 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations |
|
| October 20, 2022 |
EX-99.2 3 brhc10043119ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement - Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal of achieving accelerated enrollment - ATLANTA, October 20, 2022 - Femasys Inc. (NAS |
|
| October 12, 2022 |
Exhibit 99.1 FEMASYS INC. ANNOUNCES THE APPOINTMENT OF CHRISTINE THOMAS AS SENIOR VICE PRESIDENT OF REGULATORY AND CLINICAL AFFAIRS -Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory agencies and guidance in the total product lifecycle of medical devices- ATLANTA, October 12, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical comp |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 6, 2022 |
Exhibit 99.1 Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control - Company remains on track to file an investigational device exemption (IDE) for a pivotal trial to support a pre-market authorization (PMA) in the first quarter of 2023- ATLANTA, October 6, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwid |
|
| October 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 29, 2022 |
EX-99.1 2 brhc10042396ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team - FemCerv® is the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care - - Company expands management team with the hi |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys In |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2022 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update - Continued focus and progress with FemaSeed? and FemBloc? biomedical product candidates in development - FemCerv? and FemCath? commercial availability expected by year-end ATLANTA, August 10, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's |
|
| August 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 2, 2022 |
EX-99.1 2 brhc10040312ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Disrupting Convention in Women’s Health Through Continuous Innovation August 2022 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but |
|
| July 13, 2022 |
Femasys Inc. Common Stock Preferred Stock Debt Securities TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-266001 PROSPECTUS ? Femasys Inc. ? $150,000,000 ? Common Stock Preferred Stock Debt Securities Warrants Rights Units From time to time, we may offer up to $150,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, red |
|
| July 12, 2022 |
Piper Sandler The date of this prospectus is July 12, 2022. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-266001 PROSPECTUS Up to $8,800,000 ? Common Stock We have entered into an Equity Distribution Agreement, dated July 1, 2022 (the ?Equity Distribution Agreement?), with Piper Sandler & Co. (?Piper Sandler? or the ?Sales Agent?) relating to shares of our common stock offered by this prospectus. In accordance with the terms of th |
|
| July 7, 2022 |
CORRESP 1 filename1.htm July 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Femasys Inc. Registration Statement on Form S-3 File No. 333-266001 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Femasys Inc. (the “Registrant”) here |
|
| July 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Commo |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| July 1, 2022 |
FEMASYS INC., AS ISSUER, AS TRUSTEE, DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS EX-4.3 3 ny20004690x1ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 FEMASYS INC., AS ISSUER, AND [TRUSTEE], AS TRUSTEE, INDENTURE DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securit |
|
| July 1, 2022 |
Femasys Inc. EQUITY DISTRIBUTION AGREEMENT EX-1.2 2 ny20004690x1ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 Femasys Inc. EQUITY DISTRIBUTION AGREEMENT July 1, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Femasys Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to tim |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2022 |
EX-99.1 2 brhc10037410ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022 Furthers advancement of much-needed minimally invasive technologies for underserved areas of women’s health with pending commercialization of products, FemCerv® and FemCath™ expected by year-end Continued progress with FemaSeed and FemBloc biomedical produc |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys I |
|
| April 26, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by |
|
| April 26, 2022 |
DEFA14A 1 ny20003948x3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. ( |
|
| March 24, 2022 |
EX-4.1 2 brhc10035438ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK Capital Structure The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation (the “Charter”) and amended and restated bylaws (the “Bylaws”) are summaries and are qualified by reference to the Charter and the Bylaws, each of which is filed as an exh |
|
| March 24, 2022 |
Calculation of Filing Fee Tables Form S-8 EX-FILING FEES 4 brhc10035551ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registra |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 24, 2022 |
EX-99.1 2 brhc10035665ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021 Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health ATLANTA, March 24, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by develo |
|
| March 24, 2022 |
Calculation of Filing Fee Tables Form S-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| February 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 28, 2022 |
Exhibit 99.1 Disrupting Convention in Women?s Health Through Continuous Innovation February 2022 Corporate Presentation 1 Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectation |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 24, 2022 |
EX-10.1 2 brhc10034387ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of February 28, 2022 by and between Femasys Inc., a Delaware corporation (the “Company”), and Dov Elefant (the “Executive”). The date on which this Agreement becomes effective shall be referred to herein as the “Effective Date.” Recitals WHEREAS, the Compa |
|
| February 24, 2022 |
INDUCEMENT STOCK OPTION AGREEMENT EX-10.2 3 brhc10034387ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 INDUCEMENT STOCK OPTION AGREEMENT THIS INDUCEMENT STOCK OPTION AGREEMENT (this “Agreement”) is between Femasys Inc., a Delaware corporation (the “Company”), and [●] (the “Grantee”) and is made as of [●], 2022. RECITALS WHEREAS, the Company maintains the Femasys Inc. 2021 Equity Incentive Plan (as it may be amended and/or restated from time |
|
| February 24, 2022 |
EX-99.1 4 brhc10034387ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer - Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages - ATLANTA, February 24, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worl |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 20, 2022 |
EX-99.1 2 brhc10032968ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member - Industry leader Wendy Perrow brings decades of expertise in fundraising, global product launches and corporate strategy to the Femasys team – ATLANTA, January 20, 2022 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aimi |
|
| January 5, 2022 |
Exhibit 99.1 Disrupting Convention in Women?s Health Through Continuous Innovation January 2022 Corporate Presentation Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations a |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femas |
|
| November 12, 2021 |
EX-10.1 2 brhc10030485ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (“Agreement”), effective as of the date last signed below (the “Effective Date”), is by and between Femasys Inc., a Delaware corporation with offices located at 3950 Johns Creek Court, Suite 100, Suwanee, Georgia 30024 (“Client”) and BEspoke Medical Affairs Solutions, LLC, a Massachu |
|
| November 10, 2021 |
Exhibit 99.1 Femasys Inc. Announces Financial Results for the Third Quarter of 2021 - Up to 792-patient, pivotal LOCAL trial progressing for FemaSeed? after receipt of investigational device exemption (IDE) submission approval ? - Femasys added to the Russell Microcap? Index in Q3 - ATLANTA, Nov. 10, 2021 - Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women?s needs worldwide by |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 20, 2021 |
Femasys Inc. To Join the Russell Microcap Exhibit 99.1 Femasys Inc. To Join the Russell Microcap? Index ATLANTA, September 20, 2021 - Femasys Inc. (NASDAQ: FEMY) (?Femasys? or the ?Company?), a biomedical company developing a suite of product candidates to transform women?s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap? Index today when the U.S. |
|
| September 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 1, 2021 |
EX-99.1 2 brhc10028631ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer - Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys - ATLANTA September 1, 2021 - Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to t |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2021 |
Femasys Inc. Announces Financial Results for the Second Quarter of 2021 Exhibit 99.1 Femasys Inc. Announces Financial Results for the Second Quarter of 2021 Completed initial public offering (?IPO?) raising net proceeds of $31.6 million Appointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experience Initiated 792-patient, pivotal LOCAL trial after receipt of investigational device exemption (IDE) submission approval for |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys In |
|
| July 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 20, 2021 |
EX-99.1 2 brhc10027055ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers Atlanta, GA. - July 20, 2021 - Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced |
|
| July 13, 2021 |
EX-99.1 2 brhc10026833ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Transforming Women’s Healthcare ©2021 Femasys Inc. Corporate PresentationJuly 2021 Forward Looking Statements 2 This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to curren |
|
| July 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Femasys Inc. (Exact name of registrant as specified in its charter) Delaware 001-40492 11-3713499 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 22, 2021 |
BYLAWS FEMASYS INC. (the “Corporation”) ARTICLE I EX-3.2 3 nt10019541x13ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FEMASYS INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, |
